Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is well-positioned for long-term success in the metabolic disease treatment market. The strong correlation between ablation length and weight loss success in patients, along with the potential for RJVA-001 to offer a one-time gene therapy solution for type 2 diabetes, present a promising outlook for the company's future. Additionally, the expected FDA approval filing for Revita by the end of the year further supports the company's potential for growth and success.

Bears say

Fractyl Health is a clinical-stage metabolic therapeutics company focused on innovative treatments for obesity and T2D. Despite their promising lead product candidate, Revita, there are several risks to consider, including the potential for failed clinical trials, dilutive capital raises, and noncompliance with exchange requirements. However, the recent introduction of the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway may benefit Revita's development and accelerate time to broad Medicare coverage. If approved, this could enhance the near-term commercial outlook and bolster the long-term value proposition of the company's one-time procedural therapy.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.